Work

Tacrolimus and Sirolimus as GVHD Prophylaxis for Sibling Donor Hematopoietic Stem Cell Transplant (HCT) Using Three Conditioning Regimens; Fludarabine-Melphalan, FTBI-VP16, and Busulfan-Cyclophosphamide

Year: 2009

Type: article

Abstract: Based on encouraging phase II data, we prospectively tested the combination of tacrolimus and sirolimus (tacro/siro) as GVHD prophylaxis in patients undergoing HLA-matched sibling donor HCT. Eighty-five patients were stratified according to conditioning regimen as follows: fludarabine-melphalan (FluMel: n = 46); FTBI-VP16 (TBI: n = 28), and busulfan-cyclophosphamide (BuCy: n = 11). The median age was 47 years (range: 10–67). The patient diagnoses were AML (33), ALL (18), NHL/HD (11/3), MDS (6), CML (5), myeloma (3), MPD (3), and CLL (1).

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2008.12.276